Skip to content
Parakho

Shukra Pharmaceuticals Ltd

NSE SHUKRAPHARBSE 524632

Q1 FY27, unaudited

Revenue
₹23.52 Cr
Profit after tax
₹12.96 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year ago6M FY26
Revenue from operations23.52—6.32
Other income0.54—0.95
Total income24.06—7.27
Employee benefit expense4.39—0.37
Finance costs0.43—0.26
Depreciation & amortisation1.08—1.01
Total expenses5.89—6.89
Profit before tax18.17—0.38
Tax expense5.21—2.10
Profit after tax12.96—-1.72
Total comprehensive income12.96—-1.80
Earnings per share
Earnings per share, basic₹0.30₹-0.04
Earnings per share, diluted₹0.30₹-0.04

Q1 FY27 — unaudited, from the company’s filing with BSE. Source

6M FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Shukra Pharmaceuticals Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 49 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.